SynthesisEpidemiology and infection2019
The prevalence, temporal trends, and geographical distribution of HIV-1 subtypes among men who have sex with men in China: A systematic review and meta-analysis.
Synthesis in Epidemiology and infection, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Using HIV Risk Self-Assessment Tools to Increase HIV Testing in Men Who Have Sex With Men in Beijing, China: App-Based Randomized Controlled Trial.Journal of medical Internet research · 2023Trial
- Evolving HIV-1 epidemiology, drug resistance and socio-demographics among blood donors in Dalian, Northeastern China, 2011-2024.Vox sanguinis · 2026Article
- Co-receptor usage in distinct phylogenetic clusters of HIV-1 CRF01_AE is associated with differential immune reconstitution after antiretroviral therapy.Microbiology spectrum · 2026Article
- Molecular network characteristics and transmissible drug resistance of HIV-1 CRF55_01B in Yunnan Province.BMC infectious diseases · 2026Article
- HIV Risk Profiles and Pre-Exposure Prophylaxis and Postexposure Prophylaxis Uptake Among Men Who Have Sex With Men in China: Cross-Sectional Latent Class Analysis.JMIR public health and surveillance · 2026Article
- Developing and evaluating a novel rapid test for recent HIV-1 infection: comparison with commercial LAg-EIA assays.Journal of clinical microbiology · 2026Article
- Epidemic dynamics and clinical characteristics of HIV-1 CRF07_BC_N and CRF07_BC_O in Shanghai, 2017-2023.Virulence · 2025Article
- Prevalence, dynamic change and spatial distribution of HIV-1 CRF119_0107 from 2019 to 2024 in Nanjing, China: a genomic and spatial epidemiological analysis.Virology journal · 2025Article
- Molecular transmission network analysis of newly diagnosed HIV-1 infections in Ningbo from 2018-2022.Frontiers in microbiology · 2025Article
- Differences in HIV-related knowledge, attitudes, and behaviors among men who have sex with men (MSM): comparison between HIV-positive and HIV-negative college students.Frontiers in public health · 2025Article
- Identification of the Near Full-Length Genome of a Novel HIV-1 CRF01_AE/CRF07_BC Recombinant in Hebei Province, China.AIDS research and human retroviruses · 2024Article
- HIV-1 drug resistance and genetic transmission networks among patients with sexually transmitted HIV in Ningxia, China.Frontiers in public health · 2024Article
- Article
- Article
- Impact factors of Blastocystis hominis infection in persons living with human immunodeficiency virus: a large-scale, multi-center observational study from China.Infectious diseases of poverty · 2023Observational
- Characterization of two novel HIV-1 second-generation recombinants (CRF01_AE/CRF07_BC) identified in Hebei Province, China.Frontiers in microbiology · 2023Article
- Enhanced Transmissibility and Decreased Virulence of HIV-1 CRF07_BC May Explain Its Rapid Expansion in China.Microbiology spectrum · 2022Article
- Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.Current HIV research · 2022Article
- The Molecular Epidemiological and Immunological Characteristics of HIV-1 CRF01_AE/B Recombinants in Nanjing, China.Frontiers in microbiology · 2022Article
- Multiple CRF01_AE/CRF07_BC Recombinants Enhanced the HIV-1 Epidemic Complexity Among MSM in Shenyang City, Northeast China.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this meta-analysis was to provide a comprehensive overview of human immunodeficiency virus (HIV)-1 subtypes and to investigate temporal and geographical trends of the HIV-1 epidemic among men who have sex with men (MSM) in China. Chinese and English articles published between January 2007 and December 2017 were systematically searched. Pooled HIV-1 prevalence was calculated, and its stability was analysed using sensitivity analysis. Subgroups were based on study time period, sampling area and prevalence. Publication bias was measured using Funnel plot and Egger's test. A total of 68 independent studies that included HIV-1 molecular investigations were eligible for meta-analysis. Circulating recombinant form (CRF) 01_AE (57.36%, 95% confidence interval (CI) 53.76-60.92) was confirmed as the most prevalent HIV-1 subtype among MSM in China. Subgroup analysis for time period found that CRF01_AE steadily increased prior to 2012 but decreased during 2012-2016. Further whereas CRF07_BC increased over time, B/B' decreased over time. CRF55_01B has increased in recent years, with higher pooled estimated rate in Guangdong (12.22%, 95% CI 10.34-13.17) and Fujian (8.65%, 95% CI 4.98-13.17) provinces. The distribution of HIV-1 subtypes among MSM in China has changed across different regions and periods. HIV-1 strains in MSM are becoming more complex. Long-term molecular monitoring in this population remains necessary for HIV-1 epidemic control and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.